

**Minutes of the March 4, 2011
Pharmacy & Therapeutics (P&T) Committee Meeting
SD Department of Social Services, Medical Services Division**

Members present

Bill Ladwig, R.Ph; Rick Holm, M.D.; Debra Farver, PharmD.; Willis Sutliff, M.D.; Galen Goeden, R.Ph; Dana Darger, R.Ph; James Engelbrecht, M.D.

Members absent

Timothy Soundy, M.D.

DSS staff present

Mike Jockheck, RPh., Larry Iversen, Director of Medical Services

HID staff present

Candace Rieth, Pharm.D.

Administrative Business

The P&T meeting was called to order by D. Darger at approximately 1:00pm. The minutes of the December 10, 2010 meeting were presented. W. Sutliff made a motion to approve. D. Farver seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

C. Rieth presented an overview of the prior authorization (PA) activity for January 2011. There were a total of 3,106 PAs processed in the month of January, with 97.39% of those requests responded to in less than 8 hours. There were 2,617 (84%) requests received electronically and 489 (16%) requests received by fax. In response to a request from the committee, C. Rieth presented the number of approvals and denials, by form type, for the faxed (manual) PA requests.

Analysis of the Top 15 Therapeutic Classes

C. Rieth reviewed the Top 15 Therapeutic Classes by total cost of claims from 10/01/2010 – 12/31/2010. The top five classes were antipsychotics, cerebral stimulants, amphetamines, adrenals, and antidepressants. The top 15 therapeutic classes make up 42.28% of total claims. C. Rieth also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 16.83% of total claims.

Treximet Review

C. Rieth presented clinical information, claims data, and a prior authorization form for Treximet. B. Felt, representing GSK, spoke regarding Treximet. B. Ladwig made a motion asking the DUR Board to review all patients using migraine medication, their frequency of use and concomitant medications. R. Holm seconded the motion. HID is in the process of developing a criterion for DUR profile review that will address patients receiving chronic triptan therapy with no evidence of preventative migraine therapy. J. Engelbrecht made a motion to place a prior authorization on the triptan class with failure of sumatriptan being the criteria for approval. R. Holm seconded the motion. The motion was approved unanimously. Because Treximet was the only triptan on the agenda, the triptan class will be an agenda item for the June 2011 meeting.

Zuplenz and Granisol Review

C. Rieth presented clinical and cost information for Zuplenz and Granisol. There was no public comment. D. Farver made a motion to place Zuplenz and Granisol on prior authorization with failure of a generic 5-hydroxytryptamine-3 receptor antagonist or other anti-nausea medication. G. Goeden seconded the motion. The motion was approved unanimously.

Multiple Sclerosis Agents Review

C. Rieth presented clinical information and data for agents used to treat multiple sclerosis. R. Finch, representing Biogen, spoke regarding Avonex and Tysabri. C. Jones, representing Acorda, spoke regarding Ampyra. J. Porter, representing Novartis, spoke regarding Gilenya. B. Ladwig made a motion to place medications used to treat multiple sclerosis on prior authorization. W. Sutliff seconded the motion. The motion was approved unanimously. Forms and criteria will be brought to the June meeting for review.

Ophthalmic Antihistamines

C. Rieth presented clinical information and data for ophthalmic antihistamines. There was no public comment. W. Sutliff made a motion to place ophthalmic antihistamines on prior authorization. D. Farver seconded the motion. The motion was approved unanimously. A prior authorization form and criteria will be brought to the June meeting for review.

Oxycontin and Caffeine Citrate Review

At the December meeting, the committee asked for a review of the diagnoses of patients taking Oxycontin and the diagnoses and ages of patients using caffeine citrate. C. Rieth reviewed diagnoses and ages for Oxycontin and caffeine citrate. There was no public comment. W. Sutliff made a motion to add Oxycontin to the Name Brand Narcotics PA form. G. Goeden seconded the motion. The motion was approved unanimously. Caffeine citrate utilization (diagnoses and ages) appeared appropriate and the committee tabled this topic.

Zyvox Review

At the December meeting, the committee requested a review of patients taking Zyvox and their diagnoses. C. Rieth presented this information. L. Puznick, representing Pfizer, spoke regarding Zyvox. After committee review, the topic was tabled for re-review in six months.

P&T Committee Members

L. Iversen, Director of Medical Services, spoke regarding committee vacancies. The pharmacy association and medical association have both been contacted for suggestions. Committee members are appointed by the governor. An update will be given in June. L. Iversen also extended his gratitude towards committee members that will no longer be serving in the future.

The next meeting date is scheduled for June 10, 2011. The location will be updated on the website as soon as possible. A motion was made by G. Goeden at 2:55pm to adjourn the SD Medicaid P&T meeting. D. Farver seconded the motion. Motion passed unanimously and the meeting was adjourned.